FSH is synthesized in the pituitary by gonadotrope cells. By binding to and interacting with its cognate receptor [FSH receptor (FSHR)] in the gonads, this gonadotropin plays a key role in the control of gonadal function and reproduction. Upon activation, the FSHR undergoes conformational changes leading to transduction of intracellular signals, including dissociation of G protein complexes into components and activation of several associated interacting partners, which concertedly regulate downstream effectors. The canonical G s /cAMP/protein kinase A pathway, considered for a long time as the sole effector of FSHR-mediated signaling, is now viewed as one of several mechanisms employed by this receptor to transduce intracellular signals in response to the FSH stimulus. This complex network of signaling pathways allows for a fine-tuning regulation of the gonadotropic stimulus, where activation/inhibition of its multiple components vary depending on the cell context, cell developmental stage, and concentration of associated receptors and corresponding ligands. Activation of these multiple signaling modules eventually converge to the hormone-integrated biological response, including survival, proliferation and differentiation of target cells, synthesis and secretion of paracrine/autocrine regulators, and, at the molecular level, functional selectivity and differential gene expression. In this mini-review, we discuss the complexity of FSHRmediated intracellular signals activated in response to ligand stimulation. A better understanding of the signaling pathways involved in FSH action might potentially influence the development of new therapeutic strategies for reproductive disorders. (Endocrinology 159: 3020-3035, 2018) F SH or follitropin is synthesized in the anterior pituitary gland by gonadotrope cells. By binding to its cognate receptor in the female and male gonads, this gonadotropin plays a central role in the control of gonadal function and reproduction (1, 2). The FSH receptor (FSHR) belongs to the highly conserved subfamily of the G protein-coupled receptor (GPCR) superfamily, the socalled Rhodopsin family and, more specifically, to the d group of this large class of GPCRs (3). As other structurally related glycoprotein hormone receptors [the LH-chorionic gonadotropic hormone receptor (LHCGR) and the TSH receptor (TSHR)], the FSHR is composed of a large NH 2 -terminal extracellular domain (ECD), where recognition and binding of its cognate ligand occur. The ECD is structurally linked by the so-called hinge region to the transmembrane domain (TMD),
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The FSHR is primarily expressed by the gonads (5). In the testis, this receptor is located at the basolateral Sertoli cell surface, where it supports cell growth and maturation, and thereby spermatogenesis (8) ; in the ovary, the FSHR is expressed in the granulosa cells where FSH stimulation regulates growth and maturation of ovarian follicles and estrogen production (1) . For many years the FSHR was thought to be localized exclusively in the gonads; nevertheless, new evidence from studies in experimental animals and in humans have suggested that this receptor may also be present in extragonadal tissues where FSH may have distinct physiological roles (9) . Nonetheless, some of these extragonadal tissues as targets for FSH action have been recently questioned (10) , indicating that further studies are still required to validate the existence of extragonadally expressed FSHRs.
Studies on other GPCRs, as well as on the FSHR, have shed some light on the mechanisms that presumably lead to FSHR activation and signal transduction. It appears that FSH primarily binds to the large ECD and that extracellular loops 1 and 3, which are extracellular projections of the TMD, represent potential secondary gonadotropin binding sites (11) . Upon FSH binding, the transmembrane helices (particularly the TMD helices 5, 6, 3, and 7) present a series of conformational changes and rearrangements that are transmitted down the intracellular extensions of the a helices and associated intracellular domains (loops and C-tail; Fig. 1 ). This reorganization in intracellular domains in turn allows accommodation and activation of a number of effectors, including several receptor-coupled G proteins and other associated proteins and interacting partners, triggering the activation of a number of downstream signaling cascades that will eventually lead to a biological effect. An interesting nuance of this and other GPCRs is that the a helices conforming the TMD may oscillate between multiple conformations, which will define activation of several or distinct signaling pathways and account for biased signaling (5, (12) (13) (14) . These multiple mechanisms explain the recruitment of manifold signaling molecules to the complex signaling network activated by the FSHR during follicular and Sertoli cell maturation. Figure 1 . Schematic representation of the human FSHR with the cytoplasmic face of the TMD and the intracellular COOH terminus (C-tail) magnified and the extracellular domain removed at residue 352. The schematics show the locations of sequences, motifs, and residues involved in internal agonist activity (FNPCEDIMGY sequence shaded in dark red); G protein coupling and receptor activation [ERW motif, NPXXY motif, and BXXBB motif reversed at the intracellular loop (IL) 3]; interaction with APPL1 (residues 393, 394, and 399 at the IL1), 14-3-3t (IL2), ubiquitin, and PKC2 binding (IL3); receptor trafficking [F(X 6 )LL and BXXBB motif reversed at the NH 2 -terminal end of the C-tail]; phosphorylation of the receptor by GRK (putative class B cluster); palmitoylation (Cys644, Cys646, and Cys672); and postendocytic fate (residues 684 and 688 to 690). Also indicated is the location of the most common FSHR polymorphism (Asn680, light yellow circle) as well as of inactivating (red circles) and activating (green squares) FSHR mutations involving the TMD, extracellular loops (ELs), and IL3, which may impact receptor trafficking and/or activation and signaling [reviewed in Ulloa-Aguirre et al. (4), Ulloa-Aguirre and Zariñán (5), and Ulloa-Aguirre et al. (6) ]; the mutation at position M512 (magenta circle in the EL2) has been associated with biased signaling (7) . Numbering of the amino acid residues includes the leader sequence.
In this review, we provide a brief overview of the multifaceted aspects of FSHR transduction, signaling, and biological actions.
Signal Transduction at the FSHR: Signaling Pathways, Interacting Partners, and Networks
Most investigators agree that the effects of gonadotropins on the differentiated function of their target cells are mainly mediated by the activation of the canonical G s /adenylyl cyclase/cAMP/protein kinase A (PKA) pathway, which subsequently leads to cAMP response element binding protein (CREB) phosphorylation and modulation of gene transcription (5, (15) (16) (17) (18) (19) (20) . Nevertheless, it is now clear that this particular signaling cascade is not the only one activated by the action of these hormones. As detailed below, gonadotropins activate additional pathways that are involved in several cellular processes as proliferation and/or differentiation and, at the molecular level, functional selectivity and differential gene expression (1, 5, 13, 14, (21) (22) (23) (24) .
The FSHR is connected via conformational selectivity to a nonlinear and complex signaling network. This network can involve either several G protein subtypes, including the G s , G i , and G q/11 proteins (25) (26) (27) (28) (29) (30) , interaction with other receptors [e.g., the IGF-1 receptor (IGF-1R) and the epidermal growth factor receptor (EGFR)] (24, (31) (32) (33) and proteins [e.g., b-arrestins, adaptor protein containing pleckstrin homology domain, phosphotyrosine binding domain, and leucine zipper motif (APPL)1, forkhead box transcription factor O (FOXO)1a (also known as forkhead homolog in rhabdomyosarcoma), and 14-3-3t] (34-39), or heterodimerization with the LHCGR (26, (40) (41) (42) . These mechanisms have been reported to regulate a number of intertwined signaling pathways, including engagement of distinct kinases [such as PKA, protein kinase C (PKC), phosphatidylinositol 3-kinase (PI3K), protein kinase B/Akt, p70S6 kinase (p70S6K), and ERK1/ 2] (1, 5, 14, 22, 24, 27, 43, 44) (Fig. 2) (45) . This complex signaling network allows for a fine-tuning regulation of the gonadotropic stimulus, where activation/inhibition of its multiple components will vary depending on the cell context, developmental stage of the host cells, and concentration of receptors and ligands (1, 9, 24, 43, (46) (47) (48) . Furthermore, preferential activation of distinct signaling modules by the FSHR occurring through stabilization of distinct FSHR conformations in response to binding of particular ligands or receptor mutations may also occur (Figs. 1 and 3) (14, 49, 50) , paving the way for designing drug candidates that may elicit selective signaling at the gonadal level (51, 52) . Let us briefly dissect the complex signaling network turned on by the activated FSHR.
Signaling through G proteins
As mentioned previously, FSH binding triggers a sequence of conformational changes within the receptor that promotes activation of intracellular signaling pathways. The primary transduction effectors described for the FSHR are heterotrimeric G proteins (15, 53, 54 ). Upon G s interaction with intracellular loops (ILs) 2 and 3 of hormone-bound FSHR on the ERW and BBXXB (B, basic residue; X, nonbasic residue) motifs ( Fig. 1) (19) , adenylate cyclase is stimulated and cAMP-dependent intracellular targets are activated. One main target of cAMP is PKA that mediates FSH-dependent signaling, including the ERK MAPK cascade that controls the Sertoli cell mitotic phase (43) . In preantral granulosa cells, FSH-dependent activation of ERK is mediated through PKA-dependent destabilization of a constitutive 100-kDa MEK phosphotyrosine phosphatase (55) , identified recently as dual specificity phosphatase 6 or DUSP6 (56) . In fact, activation of phosphatases by PKA appears to be a general mechanism whereby FSH stimulates components not only of MAPK cascades, but also of PI3K-dependent signaling, by indirectly enabling IGF-1R-transduced insulin receptor substrate 1 phosphorylation in granulosa cells (57) . In these cells, FSHdependent PKA activation also stimulates p38 MAPK, likely involved in serum-and glucocorticoid-induced kinase activation (22) and in modeling granulosa cell shape (58) . However, the relationship between FSH/ PKA and p38 MAPK phosphorylation has been recently questioned by studies in which expression of a constitutively active form of PKA in granulosa cells was not sufficient alone to activate this particular pathway (59) .
PKA is considered as the master regulator of transcription factors of the CREB/activating transcription factors family (60) (Fig. 2) . Nonetheless, in FSH-stimulated Sertoli cells, PKA regulates the activity of other nuclear targets, such as the retinoic acid receptor a (61), an important modulator of male germ cell development. More generally, PKA activity could be involved in global chromatin remodeling, as illustrated by H3 histone phosphorylation in FSH-stimulated granulosa cells (62) . Of note, the requirement of CREB itself on the FSHdependent transcriptome also needs to be reconsidered because genome-wide sequencing technologies combined with bioinformatics analyses have recently underlined that FSH-responsive genes in human granulosa cells are notably enriched in binding motifs for the GATA family of transcription factors, whereas the frequency of CREB-dependent genes is much scarcer than initially anticipated (63) . Scrutinizing FSH-regulated promoter regions at the systems level will certainly bring to light the involvement of unexpected transcriptional regulators and upstream kinases in the future.
In addition to PKA, an FSH-stimulated cAMP rise also activates the exchange proteins directly activated by cAMP (EPACs), which enhance small RAS-like GTPase Rap1 activity (24) . EPAC is presumably involved in the activation of protein kinase B/Akt (22) , a PI3K target whose activity is counteracted by phosphatase and tensin homolog deleted in chromosome 10 (PTEN) to cease Sertoli cell proliferation (64) . Likewise, in granulosa cells, Akt neutralizes the antiproliferative effect of AMPactivated protein kinase (65, 66) and promotes the phosphorylation and nuclear exclusion of FOXO1a, one of its prominent substrate that also hampers the G1/S phase transition. Interestingly, recent work has revealed that FOXO1a controls the expression of most FSH-responsive genes in these cells (67) . Many of these genes correspond to those involved in autophagy (67, 68) , and recent studies suggest that FSH might protect granulosa cells from atresia in part by preventing mitophagy Figure 2 . A simplified overview of the FSHR signaling network. The color code, depending on the arbitrarily main effector, is as follows: green for PI3K-dependent signaling, orange for cAMP-dependent signaling, red for b-arrestin-dependent signaling, regardless that some signaling effectors (e.g., ERK or p70S6K) are commonly activated by these three pathways. Mechanistic details have been omitted for the sake of clarity. Of note, the phosphorylation state of the FSHR conveyed by G ai -interacting protein C terminus (GIPC) is not known. This network has been established by using the Cell Designer algorithm (45) , and the meaning of symbols is shown in the rectangle at the bottom. AC, adenylyl cyclase; AMPK, AMP-activated protein kinase; DAG, diacylglycerol; DUSP, dual specificity phosphatase 6; eIF4, eukaryotic translation initiation factor 4; PARK, E3 ubiquitin protein ligase parkin; PINK, PTEN-induced putative kinase; PIP3, phosphatidylinositol 3,4,5-triphosphate; VEE, very early endosome.
(69). The mechanisms involved encompass FOXO1a nuclear exclusion via PI3K/Akt/mammalian target of rapamycin (mTOR) activation and inhibition of E3 ubiquitin ligase Parkin recruitment in the outer membrane of damaged mithochondria by PTEN-induced putative kinase 1 (69) . Not only G s -dependent but also b-arrestin-dependent signaling might transduce the antiatretic protective effect of FSH, as shown recently in granulosa cells (70) .
Both PKA and Akt-dependent pathways cooperatively interact to stimulate mTOR and p70S6K, ultimately leading to mRNA translation (48, 71, 72, 73) (Fig 2) . Translational regulation of mRNA in response to FSH has been proposed initially in granulosa cells (71, 74) . During granulosa cell proliferation, hormone-bound FSHR leads to G s -dependent and ERK-mediated phosphorylation of TSC2 (tuberin), an mTOR effector that stimulates p70S6K activity, ultimately leading to enhanced cyclin D2 expression (74, 75) . Through the PI3K/ Akt/mTOR pathway, FSH stimulates the expression of hypoxia-inducible factor-1 mRNA, encoding a transcription factor that regulates the expression of vascular endothelial growth factor (71) . Furthermore, activation of FSH-mediated mTOR pathway also induces the expression of some follicular differentiation markers, such as the LHCGR, inhibin-a, P450 AROM , or the bII subunit of PKA. In the testis, cAMP-and PI3K/mTOR-dependent pathways also cooperate in the activation of p70S6K by inducing phosphorylation profiles that differ according to the development stage of Sertoli cells (48, 72, 73) . This developmentally regulated phosphorylation profile of p70S6K is supported by the observation that during the Sertoli cell differentiation phase, Akt is phosphorylated directly by FSHR signaling and not via transactivation of the IGF-1R as shown in the mitotic phase (75, 76) , suggesting different properties of the PI3K-regulated network at both stages (48, 72, 73) . By using these PI3K-dependent signaling mechanisms, FSH may promote rearrangements and posttranslational modifications of initiation and elongation factors that form the translational machinery at the 5 0 untranslated region of mRNAs. For example, in Sertoli cells FSH stimulates the phosphorylation of eukaryotic translation initiation factor 4 (eIF4)G and eIF4B, a cofactor of the eIF4A RNA helicase, via mTOR and p70S6K, respectively. In only a few minutes, all these molecular events induce cap-dependent translation of mRNAs such as vascular endothelial growth factor and c-fos (72) , as well as internal ribosome entry site-dependent mRNA translation (77) . Cell responsiveness to FSH is not limited to the regulation of mRNA transcription and translation, and recent data have proposed that a complex miRNA network orchestrates the stability, and hence the dynamics, of various components of the FSH signaling network (78, 79) . For example, the stabilization of PTEN would occur through hormoneinduced degradation of miRNAs complementary to the PTEN mRNA (80) . PTEN is required for Sertoli cells to achieve terminal differentiation (64) , and its mRNA is spatially restricted at spermiation in the adluminal region of Sertoli cells (80) .
Similar to many other GPCRs, the FSHR receptor exhibits some tendency to promiscuity with other G proteins. For example, the FSHR has been reported to interact with G i when activated by particular glycosylated variants of FSH (25, 81, 82) . Likewise, in Sertoli cells at early stages of maturation, cyclin D1 expression depends in part on G i FSHR coupling (43) . Further studies are needed to determine whether the FSHR variant expressed at this stage matches with the alternative splicing product of the FSHR identified previously in granulosa cells that stimulates pertussis toxin-sensitive ERK phosphorylation but is unable to enhance cAMP levels (82) . An analogous phenomenon of signaling dicotomy has been observed in cultured rat granulosa cells when the FSHR is occupied simultaneously by FSH and FSHR-negative allosteric modulators, which promote persistent FSH-stimulated estradiol biosynthesis in the face of inhibited cAMP production (51) . Besides, at supraphysiologic concentrations (.200 ng/mL), FSH also mediates FSHR coupling to G q/11 (29, 83) , leading to increased inositol 1,4,5-triphosphate levels.
Role of FSHR-associated partners, b-arrestins, Ca 2+ mobilization, and cross-talk with other plasma membrane receptors in FSHR signaling APPL1, FOXO1a, and 14-3-3t
In addition to signaling through G proteins, the FSHR also directly interacts with a number of partners that elicit particular signaling mechanisms. These partners include, among others, the APPL1 adapter, the abovementioned FOXO1a, and 14-3-3t (34, 35, 37, 38, (84) (85) (86) . The APPL1 adapter is an important regulator of signaling and trafficking events within cells and is expressed in many tissues, including the testis and the ovary (87) . In fact, this adapter interacts with many signaling proteins in a cell type-dependent manner. APPL1 may govern signal specificity and trafficking by interacting with PI3K and Akt (88) that in turn phosphorylates FOXO1a, as well as with the small GTPase Rab5 (89), a mediator of fusion of clathrin-coated vesicles with early endosomes (90) . Studies employing a yeast interaction trap identified APPL1 as an important interacting protein with the FSHR (35, 37, 38) ; furthermore, it has been found that linking between this adapter and the FSHR occurs at the IL1, specifically at Lys393, Leu394, and Phe399 (39) (Fig. 1) . In HEK293 cells stably expressing the FSHR, APPL1 and APPL2 appear to be associated with each other via the NH 2 terminus of APPL1 in an FSH-independent manner (35, 37, 38) . Given that the FSHR associates with APPL1 and interacts with FOXO1a (which does not interact with APPL1 or APPL2) (38, 66) and that APPL1 interacts with Akt (37), it has been proposed that the interplay between a FSHR/FOXO1a complex with an activated FSHR/APPL1/Akt complex leads to FOXO1a phosphorylation and abrogation of apoptosis (23, 35) . In fact, as described above, FSH stimulation results in rapid FOXO1a phosphorylation and its exclusion from the nucleus in granulosa cells (66) . In the same vein, association of the FSHR with 14-3-3t has been mapped to the IL2, overlapping with the canonical G protein binding sites, specifically the ERW motif ( Fig. 1) (35) . The 14-3-3 proteins are involved in a number of biological processes and play an important role in regulating signaling pathways by interacting with phosphorylated signaling proteins (91) . In HEK293 cells, overexpression of 14-3-3t led to decreased cAMP levels (34), suggesting a role of 14-3-3t in FSHR/G s -mediated signal transduction. The association of APPL1, 14-3-3t, and FOXO1a with the FSHR suggests that FSH causes phosphorylated FOXO1a to be sequestered to the cytosol by 14-3-3t, with APPL1 facilitating this process.
b-Arrestins
Besides evoking ERK1/2 phosphorylation through the G s pathway, FSHR activates this particular signaling cascade through b-arrestins (43, 85) , which in addition to their well-recognized role in GPCR desensitization, internalization, and recycling (see below) have also emerged as important players in the regulation of GPCR signaling (13, 86) . The FSHR has been reported to be phosphorylated by PKA and PKC second messengerdependent kinases but also by GPCR kinases (GRKs) 2, 3, 5, and 6 in various cell culture models (36, 85, (92) (93) (94) (95) . b-Arrestins recruited to GRK2-or GRK5/6-phosphorylated FSHR have been shown to exert distinct intracellular functions in time and space: b-arrestin 1 and 2 binding to GRK2-phosphorylated FSHR leads to the internalization and recycling of the receptor, whereas phosphorylation of the FSHR by GRK5 and GRK6 is required for b-arrestin-dependent, heterotrimeric G protein-independent ERK signaling, as shown by other GPCRs (13, 85, (96) (97) (98) (99) . Concurrently, these findings are consistent with a model of phosphorylation bar code elicited by distinct GRKs that could control the conformation of b-arrestin recruited to the receptor and thereby its ability to interact with specific partners (12, (96) (97) (98) (99) (100) . A well-documented illustration is the temporal encoding of ERK activation: in contrast to G protein-mediated ERK activation, which is rapid and transient, ERK recruitment and signaling activated by b-arrestins is slower (;5 to 10 minutes to reach maximum), but protracted (t 1/2 .1 hour) (85) . It has recently been demonstrated that the 5-hydroxytryptamine 2 receptor, b 2 -adrenergic receptor, CXC-chemokine receptor 4, and the FSHR activate the ERK pathway via a mechanism involving MEK-dependent b-arrestin 2 phosphorylation at Thr383. Importantly, this agonistinduced phosphorylation of b-arrestin 2 is a necessary step for ERK recruitment to b-arrestin complex and for ERK activation (101) . More recently, G s -dependent and b-arrestin-dependent FSH signaling have been shown to cooperatively activate p70S6K, within a constitutively assembled b-arrestin/p70S6K/ribosomal protein S6 module (72, 102, 103) ; this complex controls the translation of 5 0 TOP mRNAs, a subset of mRNAs representing almost 20% of cellular mRNA abundance and that encode for ribosomal proteins, poly(A)-binding protein, and factors of the translational machinery (102-104). The cojoined action of G s -and b-arrestintransduced signaling on p70S6K contrasts with the parallel action that both effectors have on the ERK MAPK pathway, whose kinetics of phosphorylation differ depending on the transducer (G s vs b-arrestins) (50, 85, 103) . Finally, the b-arrestin-dependent intracellular signaling may be preferentially activated when the FSHR is stabilized in distinct conformations in response to particular ligands or receptor mutations, in a process known as biased agonism or functional selectivity (Fig. 3) , which is discussed below.
Ca

2+ mobilization
FSH-stimulated Ca 2+ mobilization in both granulosa and Sertoli cells has been well recognized for a long time, and it has been attributed to both rapid influx of Ca 2+ through T-type Ca 2+ channels as well as release from intracellular stores (28, 30, (105) (106) (107) (108) (109) , where G i /Gbg/ PI3K or G s -and/or G q -mediated activation of phospholipase C (PLC)b or other PLC isoforms appear to play an important role. In fact, in rat Sertoli cells, FSHR can signal through the transglutaminase Gah to promote extracellular Ca 2+ mobilization by interacting with PLCd-1 (28). Moreover, studies in human granulosa cells revealed that in addition to the regulatory roles of APPL1 described above, interaction of this adapter with the FSHR also leads to inositol 1,4,5-triphosphate production and release of Ca 2+ from intracellular stores (39) . Alternatively, it has been shown that exposure of swine granulosa cells or rat Sertoli cells to FSH leads to a rapid increase in intracellular Ca 2+ accumulation, which may occur in a cAMP-dependent (e.g., via stimulation of PLC«) and cAMP-independent (e.g., via the G q/11 bg complex) manner (26, 30, 106, 107, 110, 111) . Whatever the mechanisms involved in Ca 2+ mobilization, it seems that Ca 2+ -mediated signaling is important for FSH-regulated functional differentiation of granulosa and Sertoli cells (112-114).
Cross-talk with other plasma membrane receptors in FSHR signaling
Among the mechanisms contributing to GPCR signal pleiotropy is receptor cross-talk, which may occur either via intracellular effectors or through heterodimerization. In this regard, the tyrosine kinase receptors IGF-1R and EGFR have emerged as important functional partners of the FSHR. Regarding the former, it has been shown that ligand-activated IGF-1R and FSHR act synergistically to enhance steroidogenesis, LHCGR and inhibin-a expression, and cell proliferation in different cell contexts and species, albeit with some differences (33, 115, 116) . Additionally, both FSH and locally produced IGF-1 are essential for granulosa cells differentiation, follicle survival, and fertility (33, 117) . Signaling mediated by both receptors converge and overlap in activating distinct signaling cascades downstream of adenylyl cyclase, mainly the PI3K/Akt pathway (22, 31) . Furthermore, female mice with conditional knockdown of the IGF-1R in granulosa cells or exposed to IGF-1R inhibitor exhibited defective FSH-stimulated Akt activation and steroidogenesis, indicating the key role played by the IGF-1R on FSHR-regulated cell proliferation and differentiation (22, 31) . The molecular mechanisms proposed for the synergic effects of FSH and IGF-1 at the receptor level include the ability of activated FSHRs to inhibit dephosphorylation of the IGF-1R by protein kinase phosphatases, such as PTP-1B and Src homology 2 domain-containing phosphatase 2, both expressed in granulosa cells (118) (119) (120) . Alternatively, the interaction between molecular chaperones and IGF-1R may be enhanced, as suggested by the prevention of cyp19 and P450 scc expression in response to FSH by heat-shock protein 90 inhibition (33) .
Another receptor modulating FSH-stimulated granulosa cell proliferation and differentiation in the developing follicle is the EGFR, which participates in phosphorylation of ERK1/2 and p38MAPK in granulosa and cumulus cells of preovulatory follicles (121) (122) (123) . Thus, in addition to EPAC and Rap1 in promoting p38MAPK phosphorylation (see above), FSH-stimulated induction of EGF-like factors, such as amphiregulin (AREG; also known as aregulin), appears as well to play an important role in the PKA-independent activation of MAPK signaling in developing granulosa cells (24, 124, 125) . Additional studies have further indicated that besides promoting activation of the MAPK cascade, AREG and FSH stimulate Akt and FOXO1a phosphorylation through activation of members of the Src family of tyrosine kinases (24) . As in the case of the IGF-1/IGF-1R pathway described above, it appears that the AREG/ EGFR/RAS and FSH/FSHR signaling pathways converge on common downstream targets, mainly ERK1/2, p38MAPK, and Akt phosphorylation, leading to upregulation and downregulation in the expression of different genes that impact both follicle maturation and granulosa cell differentiation into granulosa-lutein cells exhibiting functional and steroidogenic profiles that differ from those exhibited by maturing granulosa cells (1, 123, (126) (127) (128) . The importance of the EGF/EGFR pathway in follicular maturation and ovulation is emphasized by studies in mice showing that the absence of Areg results in subfertility and decreased response to exogenous gonadotropin treatment (129) .
In addition to cross-talk with the IGF-1R and EGFR, the FSHR interacts with the structurally related LHCGR. Although the functional relationship between these two gonadotropin receptors had been well recognized for a long time, it was only recently that functional cross-talk and physical interaction between gonadotropin receptors were reported (26, 40, 41) . Hetero-oligomerization of the FSHR and LHCGR has been demonstrated using bioluminescence resonance energy transfer, fluorescence correlation spectroscopy, and, more recently, photoactivatable-localization microscopy (,10 nm resolution) (26, 130, 131) . Biochemical studies in HEK293 cells showed that when heterodimerized, FSH and LHCG receptors exhibited cross-inhibitory effects on G s signaling: heterodimerization of LHCGR with FSHR led to attenuation of LH-stimulated cAMP production, whereas when FSHR heterodimerized with LHCGR, FSH-stimulated second messenger production was mitigated (40) . More recently, Jonas et al. (26) employed photoactivatablelocalization microscopy to detect physical and functional interaction between the FSH and LHCG receptors in human granulosa-lutein cells. They found that both receptors associate as functionally asymetric heteromers, and that this association leads to prolonged LH-stimulated Ca 2+ signaling via influx of extracellular calcium in a G q/11 a-and bg-dependent manner (26) . Concurrently, these data demonstrate that gonadotropin receptors, when heterodimerized, may undergo allosteric regulation, with one receptor impacting cell signaling triggered by the other, as previously suggested (42) . Cross-talk between gonadotropin receptors may be potentially important for reproductive function, given that in vivo both receptors coexist in granulosa cells, particularly during the last stages of follicle development prior to ovulation (1).
Signal Termination and Biased Agonism
Signal termination at the FSHR is a tightly regulated multistep process known as homologous desensitization. First, GRKs rapidly phosphorylate serine/threonine residues of the FSHR COOH terminus (5, 36, 85, 93-95) . Second, b-arrestins 1 and 2 are recruited and prevent G s interaction with the core domain of the FSHR through steric hindrance (5, 54, 94, 95, 132) . Third, the amount of intracellular cAMP decreases and the receptor becomes refractory to further FSH stimulation (13, 85, 86, 133) . Following desensitization, the FSHR is rapidly internalized and predominantly resensitized, with a minor fraction of the FSHR being degraded (54, 85, 134) . Interestingly, the FSHR was recently reported to traffic to very early endosomes for its postendocytic sorting rather than early endosomes similar to most GPCRs (135-137) (Fig. 2) . In contrast with G s , which leads to full cAMP response with ,5% of FSHR occupancy, .90% of FSHR molecules need to be occupied to achieve maximal b-arrestin recruitment and internalization (54) .
Major advances in GPCR structural biology during the last decade have profoundly changed the conceptual basis of receptor activation and pharmacological efficacy. In particular, it is now appreciated that GPCRs adopt multiple inactive and active conformations that are connected to distinct transduction mechanisms (12, (138) (139) (140) (141) (142) (143) (144) (145) (146) (147) . Accordingly, it has been shown that a given ligand or receptor mutation can modify the stabilized conformation of the receptor/ligand complex, as compared with the wild-type receptor/reference ligand complex (Fig. 3) . This phenomenon is generally referred to as pharmacological bias (12, 138, 141, 144) . Practically, this conceptual framework delineates two levels of pharmacological bias. First, ligand bias that is elicited by certain ligands that stabilize a subset of the receptor conformations leads to an imbalance between the signaling pathways activated when compared with the reference agonist. Second, receptor bias that can occur in the case of mutations (e.g., in the case of FSHR Met512Ile mutation at the second extracellular loop or Ala189Val mutation at the ECD) (7, 148, 149) or of single nucleotide polymorphisms (e.g., the Asn680Ser polymorphism, Fig. 1) (150, 151) at the receptor level leads to imbalanced or impaired signaling compared with the wild-type receptor (Fig. 3) .
Different classes of small molecules capable of modulating FSHR have been identified (152) (153) (154) (155) (156) (157) , including three negative allosteric modulators (NAMs) (51, 52, 158) . ADX61623 increased the affinity of FSH binding, yet it blocked FSHR-mediated cAMP and progesterone but not estradiol production in rat primary granulosa cells, whereas in vivo, it did not affect FSH-induced preovulatory follicle development (51) . Two other NAMs, ADX68692 and ADX68693, with structural similarities to ADX61623, were subsequently shown to exhibit biased NAM activities on FSHR in rat primary granulosa cells (52, 158) : ADX68692 blocked FSHR-promoted cAMP, progesterone, and estradiol production whereas ADX68693 inhibited cAMP and progesterone with the same efficacy as ADX68692 but did not block estradiol production. Importantly, ADX68692, but not ADX68693, decreased the number of oocytes recovered in the ampullae (52) . A positive allosteric modulator (PAM), Org 214444-0, has also been described (159) ; this PAM exhibited nanomolar FSHR agonistic effects and selectivity over the structurally related LHCGR and TSHR. When coincubated with FSH, Org 214444-0 increased FSH binding and cAMP activation. Furthermore, in vivo, Org 214444-0 recapitulated the action of FSH in a model of fertility in rats. More recently, another series of small molecules acting as agonist PAMs were reported (160) (161) (162) . These thiazolidinone derivatives have been shown to activate FSHR signaling in CHO cells and to enhance estradiol production in cultured rat granulosa cells (161) . Additionally, optimization of substituted benzamides led to more FSHR-selective molecules (162) . Small molecules have also been reported to behave as competitive antagonists. First, suramin has been shown to inhibit testosterone production and FSHR signaling (163, 164) . Another compound displaying similar antagonistic properties as suramin but with much better specificity for FSHR was later described (165) . With the notable exception of the ADX series, whether these compounds lead to balanced or biased agonism/antagonism compared with FSH remains unknown and will need further investigation.
In the same line, it has long been suggested that naturally occurring FSH glycoforms may also elicit distinct effects on target cells (166) . The common a-subunit and FSHb each contain two N-linked oligosaccharides (at positions Asn52 and Asn78 on FSHa and at Asn7 and Asn24 in FSHb) that play a pivotal role in the functional properties of the hormone (167) (168) (169) (170) . Removal of the carbohydrate residue at position 78 on the a-subunit significantly increases receptor binding affinity of human FSH. Likewise, carbohydrate at position 52 on the a-subunit was found to play an essential role in signal transduction because its removal resulted in a significantly decreased potency. A hypoglycosylated FSH (FSH21/18) was 9-to 26-fold more active than fully glycosylated FSH (tetraglycosylated FSH24) in binding and functional assays (171, 172) . Another human FSH deglycosylated variant, which possesses only a-subunit oligosaccharides, was significantly more bioactive in vitro than the tetraglycosylated form of the hormone (173, 174) . In contrast, hyperglycosylated FSH enhanced the number of ovulated eggs and subsequent in vitro embryo development (175) . Interestingly, partially deglycosylated eLH behaved as a biased agonist at the FSHR, eliciting b-arrestin recruitment to FSHR as well as ERK and ribosomal protein S6 phosphorylation in a b-arrestin-dependent and G s /cAMPindependent manner (50).
The effects of FSH21/18 and FSH24 have further been studied in vivo (176) . Administration of these FSH glycoforms to Fshb-null female mice induced expression of several FSHR downstream signaling pathway components, including phosphorylated forms of CREB, PKA, Akt, p38, and p42/44 ERK substrates, and FSHregulated genes (e.g., Cyp19a, inhba, and inhbb) in a similar manner, albeit with some differences in the kinetics of response between the two glycoforms. In contrast, when FSH21/18 or FSH24 were inyected to Fshb-null males, differential upregulation and downregulation in the expression of seven (cdo1, Clu, Tbx22, Zic3, Car13, Amh and FSHr) out of nine FSHresponsive genes analyzed was observed, suggesting biased agonism of the FSH glycoforms at the Sertoli cell level in vivo (176) . Whether the functional selectivity shown by hypoglycosylated and fully glycosylated FSH is only due to differences in binding affinity to or stability of interaction with the FSHR (171, 177) , or actually to induction of distinctly different receptor conformations leading to selective activation of downstream signaling pathways, still remains to be analyzed in more detail.
Another class of potential ligand bias comes from cases where structural constraints are conveyed on the hormone by an antibody, leading to the modification of its pharmacological properties (14) . Polyclonal antipeptide antibodies against the ovine FSHb subunit led to a significant enhancement of biological activity in vivo in mice (178) . Likewise, the use of a monoclonal antibody against bovine FSH in Snell dwarf mice showed an increase in uterine weight (179) . Studies also evaluated the impact of equine chorionic gonadotropin (eCG)/anti-eCG complexes on gonadotropin bioactivities. They showed that anti-eCG IgGs were either inhibitory or hyperstimulatory on LH and FSH bioactivity (180) . Furthermore, Wehbi et al. (49) discriminated the nature of these complexes on FSH signaling and revealed their biased properties.
Conclusions
From the above discussion, it is clear that FSH-stimulated intracellular signaling is mediated through an intricate network whose dynamic properties depends on the stage of target cell development and cell context, which may in turn be regulated by numerous factors intrinsic to the cell and by the ligand. These factors include changing ligand pulse frequency and local concentrations, particular structure (166, 172, 176, (181) (182) (183) , and interaction dynamics with the FSHR (177) .
Because the multiple components of the FSHRregulated signaling network (Fig. 2) are not activated with the same amplitude or at the same time, the temporal and dynamical aspects that govern the kinetics of the biochemical reactions involved have to be considered. These complex dynamics can be approached with computational modeling using ordinary differential equations, as proposed previously for the FSHR (78, 184) . For example, in granulosa cells, FSH-induced cAMP pathway dynamics have been modeled with careful examination of steady-states and parameter sensibility (184) . Dynamic interactions between cAMP and mTOR pathways that converge onto p70S6 kinase activation by FSH or insulin were modeled using experimental data from primary Sertoli cells (48) . This model provided clues on p70S6 kinase phosphorylation rates and was experimentally validated using pharmacologically perturbed conditions. Further developments of FSHR network modeling will help to fill the gap between detailed knowledge on molecular interactions and comprehensive understanding of hormonal dynamics. Functional interactions of the FSHR with several tyrosine kinase receptors other than the IGF-1R and EGFR described above may further increase the landscape complexity. These include the neurotropic factors glial cell line-derived neurotropic factor (185) and brain-derived neurotrophic factor (186) receptors, as well as receptors of the TGFb family members (187), known to potentiate the mitogenic action of FSH in Sertoli cells and/or granulosa cells. These aspects will require further investigation.
Since the first pioneering evidence that the gonads exhibit binding sites specific for the FSHR and respond to FSH by increasing intracellular cAMP levels (16, (188) (189) (190) (191) , significant advances in our understanding of the structure and function of the FSH/FSHR system has been achieved. Nonetheless, there are still important issues that remain to be elucidated and that will require the application of new experimental paradigms, "omic" technologies (genomic, transcriptomic, and proteomic techniques), and systems biology tools to facilitate this challenging task. These issues include, for example, a more detailed elucidation of the mechanisms underlying differential gene expression and protein phosphorylation during granulosa cell differentiation and follicle maturation under the influence of FSH variants, FSH analog compounds, and FSHR allosteric modulators, which may convey important therapeutic benefits to the clinical arena. To this end, in vitro experimental models such as intact follicle culture or three-dimensional bioprosthetic ovary models that may better reproduce the physiological environment of the developing follicle may be applied; these systems might allow to explore more deeply the signaling pathways and gene expression profile induced by FSH both in target cells in their in situ arrangements and within different granulosa cell compartments throughout follicle maturation (192) (193) (194) . As mentioned above, it is important to confirm the existence of extragonadally expressed FSHRs and, if so, then to carefully dissect their corresponding signaling networks and metabolic pathways as well as gene expression profiles, which might eventually allow to assign them physiological roles according to their particular location. Integration of largescale information obtained from these techniques will undoubtedly facilitate the building up of more integrative signaling framework models that may be applied to modeling and simulating in silico the biological consequences of the intermittent FSH stimulus on its target cell in multiple-way combinations. Beyond any doubt, past and present studies represent the prologue to what remains to be unveiled. 
